logo

For the Inventor, By the Inventor

Tampa, FL, United States of America

Alejandro V Villagra

This inventor holds 11 USPTO granted patents and 5 published patent applications. Top assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of Illinois, The George Washington University. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alejandro V Villagra. Retrieved from https://idiyas.com/inventor/alejandro-v-villagra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 30(Granted Patents)


Location History:

  • Tampa, FL (US) (2016 - 2021)
  • Falls Church, VA (US) (2022 - 2024)

Company Filing History:

goldMedal8 out of 312 
 
H. Lee Moffitt Cancer Center and Research Institute, Inc.
 patents
silverMedal7 out of 2,432 
 
University of Illinois
 patents
bronzeMedal3 out of 284 
 
The George Washington University
 patents
where one patent can have more than one assignee

Years Active: 2016-2026

Loading Chart...
11 patents (USPTO):Explore Patents
1. 12522572 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2026-01-13),
2. 12024493 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2024-07-02),
3. 11472780 - Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors (2022-10-18),
4. 10918638 - Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination (2021-02-16),
5. 10576066 - Histone deacetylase as a modulator of PDLI expression and activity (2020-03-03),
6. 10227295 - Selective histone deactylase 6 inhibitors (2019-03-12),
7. 10016421 - Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination (2018-07-10),
8. 9987258 - Histone deacetylase as a modulator of PDL1 expression and activity (2018-06-05),
9. 9956192 - Selective histone deactylase 6 inhibitors (2018-05-01),
10. 9751832 - Selective histone deactylase 6 inhibitors (2017-09-05),
11. 9409858 - Selective histone deactylase 6 inhibitors (2016-08-09),

Title: Alejandro V Villagra: Innovator in Cancer Research

Introduction

Alejandro V Villagra is a prominent inventor based in Tampa, FL (US), known for his significant contributions to cancer research. With a total of 11 patents, he has made remarkable strides in the field of medicinal chemistry, particularly in the development of novel compounds for therapeutic use.

Latest Patents

Among his latest patents, Villagra has focused on isoxazole hydroxamic acids as histone deacetylase 6 inhibitors. The present disclosure provides compounds represented by Formula I and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined in the specification. These compounds are intended for use in treating diseases and conditions, such as cancer, where inhibition of HDAC provides a therapeutic benefit.

Career Highlights

Villagra has had a distinguished career, working at notable institutions such as the H. Lee Moffitt Cancer Center and Research Institute, Inc. and the University of Illinois. His work has been instrumental in advancing the understanding and treatment of cancer through innovative research and development.

Collaborations

Throughout his career, Villagra has collaborated with esteemed colleagues, including Eduardo M Sotomayor and Alan P Kozikowski. These partnerships have further enriched his research and contributed to the success of his projects.

Conclusion

Alejandro V Villagra stands out as a key figure in the field of cancer research, with a strong portfolio of patents that reflect his innovative spirit and dedication to improving therapeutic options for patients. His work continues to inspire advancements in medicinal chemistry and cancer treatment.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…